Abstract: IgA nephropathy (IgAN) is a primary glomerular disease characterized by IgA deposition in mesangial region of glomerular. As an immunomodulator, hydroxychloroquine (HCQ) is mainly used in treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune diseases. Many studies have confirmed that HCQ can reduce proteinuria in IgAN and alleoviate kidney damage. This review aims to systematically describe possible mechanism and research progress of HCQ in treatment of IgAN, and provide reliable evidence for future clinical use.